Telomir Pharmaceuticals, Inc. SEC filings TELO
Telomir Pharmaceuticals, Inc. has 147 filings in SEC EDGAR's recent list, going back to Apr 3, 2023. Its latest annual report, Form 10-K, was filed on Mar 17, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 13, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 6, 2026 (material agreement, unregistered share sale, regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | Aug 19, 2026 | — |
| DEF 14A | Proxy statement | Jul 28, 2026 | Jul 28, 2026 |
| DEFM14A | Filing | Feb 19, 2026 | — |
| DEFA14A | Additional proxy material | Feb 19, 2026 | — |
| PREM14A | Filing | Nov 20, 2025 | Nov 20, 2025 |
Showing 5 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- TELO (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- FL
- Headquarters
- Miami, FL
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1971532
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.